Full-Time

Senior Director Clinical Data Management Lead

External Data Management

Posted on 8/19/2026

Deadline 8/24/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$173.2k - $272.6k/yr

+ Annual bonus + Long-term incentive

H1B Sponsorship Available

North Wales, PA, USA + 1 more

More locations: Rahway, NJ, USA

Hybrid

Hybrid work arrangement; 10% travel required.

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
Data Visualization
Data Governance

Get referred to Merck

See people who can refer or advise you

Requirements
  • Strong understanding of end-to-end clinical data management processes and systems for data collection, data standards, cleaning and review, reporting, governance, and operational and quality metrics.
  • Deep knowledge of International Council for Harmonisation Good Clinical Practice guidelines and their application to clinical or safety data management.
  • Understanding of regulatory requirements, quality frameworks, and inspection and audit processes.
  • Experience implementing risk-based and digital data practices using data and automation to improve focus and quality.
  • Knowledge of geographic risk, escalation, and capacity-management processes.
  • Ability to use analytical and forecasting tools, including dashboards and capacity models, for resourcing, planning, and operational decisions.
  • Ability to define and enforce standards for data, tools, and solutions integration, reuse, and scalability.
  • Financial stewardship experience, including budget ownership, workforce cost modeling, and investment/value-realization frameworks.
  • Knowledge of local-subsidiary operations, including human resources, vendors, facilities, and finance, and local compliance expectations.
  • Expertise in data-product governance, including definitions, lineage, quality controls, and lifecycle management.
  • Ability to implement and execute inspection-readiness practices with process and quality partners.
  • Ability to drive high-quality clinical data collection design, validation, and delivery in alignment with protocol requirements.
  • Strategic leadership across diverse, cross-functional, and virtual teams and stakeholders.
  • Ability to negotiate and resolve conflicts while aligning divergent priorities to enterprise outcomes and enforcing clear responsibilities.
  • Ability to facilitate decision-making, coordinate work across teams, and drive timely resolution of complex issues.
  • Change leadership, executive influence, and storytelling across senior leadership levels.
  • Ability to drive large-scale change, embed innovation, and lead continuous improvement while ensuring adoption of standardized, risk-based, and digital practices.
  • People leadership, mentoring, and development capabilities across multiple levels and geographies.
  • Ability to integrate business, operational, and people dimensions into effective decisions, with budget and business acumen.
  • Ability to prioritize and perform effectively under pressure, exercise sound judgment independently, and communicate actionable feedback to direct reports.
  • Capability-building experience focused on senior-level talent development and communities of practice.
  • Fluency in English with excellent written and verbal communication skills.
  • Bachelor's degree or equivalent educational experience in life science, data, or information technology, with 13 years of data-management experience, including 5 years of people-management experience and experience in clinical data management, clinical trial operations, and managing large diverse global teams.
  • Bachelor's degree or equivalent educational experience in any other field, with 18 years of data-management experience, including 5 years of people-management experience and experience in clinical data management, clinical trial operations, and managing large diverse global teams.
  • Master's or Doctorate degree in life science, data, information technology, project management, or business, with 10 years of related industry experience in data management, including 5 years of people-management experience and experience in clinical data management, clinical trial operations, and managing large diverse global teams.
  • Master's or Doctorate degree in any other field, with 15 years of related industry experience in data management, including 5 years of people-management experience and experience in clinical management, clinical trial operations, and managing large diverse global teams.
Responsibilities
  • Provide strategic direction within the assigned country and ensure consistent execution, quality, compliance, and country-specific objectives.
  • Represent geographic and functional perspectives in leadership and enterprise forums and audits as needed.
  • Lead cross-functional collaborations with non-Global Data Management and Standards partners and enterprise support functions.
  • Communicate executive narratives on risks, trade-offs, and decisions, and champion innovation, automation, and risk-based data-management practices.
  • Lead the operating model and optimization strategy for the assigned geography.
  • Support capability development and technology adoption aligned with industry best practices and organizational priorities.
  • Align teams with Clinical Development Portfolio, Global Clinical Trial Operations, and cross-functional objectives.
  • Serve as the Global Data Management and Standards Site Head for the relevant country when assigned.
  • Partner with country and regional human resources, finance, and other business-support functions.
  • Coordinate workforce planning, resource management, and operational performance.
  • Serve as the escalation point for country issues and oversee country risk, escalation, and capacity-management processes.
  • Ensure local regulatory, business, and labor compliance.
  • Ensure inspection readiness and compliant operational controls for operational data, change management, and system releases.
  • Evaluate and implement process and technology improvements that enhance scalability, standardization, and quality.
  • Lead complex cross-functional workstreams from idea and design through implementation and value realization.
  • Support metrics governance and performance reviews to ensure portfolio health and operational efficiency.
  • Manage objectives and key results and performance metrics for the assigned geography; monitor dashboards and drive accountability.
  • Conduct enterprise and country scenario planning and implement resilience playbooks for business continuity.
  • Provide decision-ready updates and status reporting to leadership and partners.
  • Set team objectives, assign work, and set priorities while accounting for sustainable work-life balance.
  • Conduct regular check-ins and annual reviews, coach for performance, and provide recognition.
  • Develop career plans, create growth opportunities and promotion cases, and ensure appropriate training and mentoring.
  • Lead recruiting and hiring and oversee performance-management activities, including sensitive employee-relations matters with human resources.
  • Coordinate onshore, offshore, and contingent resources and ensure role clarity and effective handoffs.
  • Manage the operating budget and optimize spending against priorities.
  • Ensure team leaders effectively support and empower their individual leaders.
  • Represent the assigned capability on the Clinical Data Management leadership team.
  • Define strategic objectives and the roadmap for capability-development initiatives.
  • Establish and oversee capability governance with Global Data Management and Standards, Global Clinical Trial Operations, and enterprise digital and data initiatives.
  • Own development of critical tools, processes, and skills.
  • Drive consistent global rollout through playbooks, guidance, and implementation support.
  • Align cross-regional ways of working with partners.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.